Johanna K Ehrenstein1,2, Sander K R van Zon3, Saskia F A Duijts4,5, Roy E Stewart3, Josué Almansa3, Benjamin C Amick6, Sanne B Schagen7,8, Ute Bültmann3. 1. Community and Occupational Medicine, Department of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands. j.k.ehrenstein@umcg.nl. 2. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. j.k.ehrenstein@umcg.nl. 3. Community and Occupational Medicine, Department of Health Sciences, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands. 4. Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands. 5. Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Godebaldkwartier 419, 3511 DT, Utrecht, The Netherlands. 6. Department of Epidemiology, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 7. Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. 8. Department of Psychology, University of Amsterdam, Nieuwe Achtergracht 129-B, 1018 WT, Amsterdam, The Netherlands.
Abstract
PURPOSE: Cognitive symptoms affect cancer survivors' functioning at work. To date, cognitive symptoms trajectories in working cancer survivors and the factors associated with these trajectories have not been examined. METHODS: Data from a heterogeneous group of working cancer survivors (n = 379) of the longitudinal "Work-Life-after-Cancer" study, linked with Netherlands Cancer Registry data, were used. The Cognitive Symptom Checklist-Work was administered at baseline (within the first 3 months after return to work), 6-, 12-, and 18-month follow-up to measure self-perceived memory and executive function symptoms. Data were analyzed using group-based trajectory modeling. RESULTS: Four trajectories of memory and executive function symptoms were identified. All memory symptoms trajectories were stable and labeled as "stable-high" (15.3% of the sample), "stable-moderately high" (39.6%), "stable-moderately low" (32.0%), and "stable-low" (13.0%). Executive function symptoms trajectories changed over time and were labeled as "increasing-high" (10.1%), "stable-moderately high" (32.0%), "decreasing-moderately low" (35.5%), and "stable-low" (22.4%). Higher symptoms trajectories were associated with older age, longer time from diagnosis to return to work, more quantitative work demands, and higher levels of depressive symptoms at baseline. CONCLUSIONS: In cancer survivors who returned to work, four cognitive symptoms trajectory subgroups were identified, representing different but relatively stable severity levels of cognitive symptoms. IMPLICATIONS FOR CANCER SURVIVORS: To identify cancer survivors with higher symptoms trajectories, health care providers should assess cognitive symptoms at baseline after return to work. In case of cognitive symptoms, it is important to also screen for psychological factors to provide appropriate guidance.
PURPOSE: Cognitive symptoms affect cancer survivors' functioning at work. To date, cognitive symptoms trajectories in working cancer survivors and the factors associated with these trajectories have not been examined. METHODS: Data from a heterogeneous group of working cancer survivors (n = 379) of the longitudinal "Work-Life-after-Cancer" study, linked with Netherlands Cancer Registry data, were used. The Cognitive Symptom Checklist-Work was administered at baseline (within the first 3 months after return to work), 6-, 12-, and 18-month follow-up to measure self-perceived memory and executive function symptoms. Data were analyzed using group-based trajectory modeling. RESULTS: Four trajectories of memory and executive function symptoms were identified. All memory symptoms trajectories were stable and labeled as "stable-high" (15.3% of the sample), "stable-moderately high" (39.6%), "stable-moderately low" (32.0%), and "stable-low" (13.0%). Executive function symptoms trajectories changed over time and were labeled as "increasing-high" (10.1%), "stable-moderately high" (32.0%), "decreasing-moderately low" (35.5%), and "stable-low" (22.4%). Higher symptoms trajectories were associated with older age, longer time from diagnosis to return to work, more quantitative work demands, and higher levels of depressive symptoms at baseline. CONCLUSIONS: In cancer survivors who returned to work, four cognitive symptoms trajectory subgroups were identified, representing different but relatively stable severity levels of cognitive symptoms. IMPLICATIONS FOR CANCER SURVIVORS: To identify cancer survivors with higher symptoms trajectories, health care providers should assess cognitive symptoms at baseline after return to work. In case of cognitive symptoms, it is important to also screen for psychological factors to provide appropriate guidance.
Authors: Andy S K Cheng; Yingchun Zeng; Xiangyu Liu; Shaxin Liu; Stella W C Cheng; Cindy T T Kwok; Raymond C K Chung; Jianfei Xie; Michael Feuerstein Journal: J Cancer Surviv Date: 2018-09-18 Impact factor: 4.442
Authors: H F Dorland; F I Abma; C A M Roelen; R E Stewart; B C Amick; U Bültmann; A V Ranchor Journal: Psychooncology Date: 2018-07-12 Impact factor: 3.894
Authors: Heleen F Dorland; Femke I Abma; Corné A M Roelen; Roy E Stewart; Benjamin C Amick; Adelita V Ranchor; Ute Bültmann Journal: Int J Cancer Date: 2017-07-19 Impact factor: 7.396
Authors: Lise Paquet; Shailendra Verma; Barbara Collins; Anne Chinneck; Marc Bedard; Xinni Song Journal: Psychooncology Date: 2017-02-10 Impact factor: 3.894
Authors: Michelle C Janelsins; Charles E Heckler; Luke J Peppone; Charles Kamen; Karen M Mustian; Supriya G Mohile; Allison Magnuson; Ian R Kleckner; Joseph J Guido; Kelley L Young; Alison K Conlin; Lora R Weiselberg; Jerry W Mitchell; Christine A Ambrosone; Tim A Ahles; Gary R Morrow Journal: J Clin Oncol Date: 2016-12-28 Impact factor: 44.544
Authors: Johanna K Ehrenstein; Sander K R van Zon; Saskia F A Duijts; Boukje A C van Dijk; Heleen F Dorland; Sanne B Schagen; Ute Bültmann Journal: J Cancer Surviv Date: 2020-01-15 Impact factor: 4.442